Can-Fite BioPharma American Depositary Shares
CANF
14 hedge funds and large institutions have $950K invested in Can-Fite BioPharma American Depositary Shares in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
1,286% more capital inflows, than outflows
Capital inflows: $946K | Capital outflows: $68.3K
4.83% more ownership
Funds ownership: 2.2% → 7.03% (+4.8%)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$898K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$22.2K |
| 3 |
Two Sigma Securities
New York
|
+$18.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.36K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$852 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XTX Topco
George Town,
Cayman Islands
|
-$22.6K |
| 2 |
Virtu Financial
New York
|
-$20K |
| 3 |
Morgan Stanley
New York
|
-$15.3K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$5.76K |
| 5 |
BPI
BFC Planning, Inc.
Cedar Rapids,
Iowa
|
-$3.7K |
CANF Hedge Fund Activity: Q2 2025 in Review
14 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2025, worth a combined $950K — up 381% from $198K a quarter earlier.
Fund positioning in CANF was balanced in Q2 2025: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $898K. The largest seller was XTX Topco, exiting entirely with an estimated $22.6K sold.
- 14 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $950K of Can-Fite BioPharma American Depositary Shares stock for Q2 2025, up 381% quarter-over-quarter.
- 4 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2025 and 4 closed out, a net change of 0 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2025 was Sabby Management, an estimated $898K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2025 was XTX Topco, an estimated $22.6K sold.
Based on aggregated 13F filings for Q2 2025.